Sanofi (SNY) announced the immediate adoption of influenza strains selected by the Food and Drug Administration to advance the manufacturing ...

Sanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.

In a report released today, Florent Cespedes from Bernstein maintained a Buy rating on Sanofi (SNYNF – Research Report), with a price target of ...